Bile acid sequestrants and diabetes: Introduction and overview to the supplement

I. Jialal

Research output: Contribution to journalArticle

Abstract

Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.

Original languageEnglish (US)
JournalMetabolic Syndrome and Related Disorders
Volume8
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 1 2010

Fingerprint

Bile Acids and Salts
LDL Cholesterol
Glycosylated Hemoglobin A
Blood Pressure
Colesevelam Hydrochloride
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Bile acid sequestrants and diabetes : Introduction and overview to the supplement. / Jialal, I.

In: Metabolic Syndrome and Related Disorders, Vol. 8, No. SUPPL. 1, 01.12.2010.

Research output: Contribution to journalArticle

@article{0176ac6dac5c4bf1812d362f1672dbec,
title = "Bile acid sequestrants and diabetes: Introduction and overview to the supplement",
abstract = "Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.",
author = "I. Jialal",
year = "2010",
month = "12",
day = "1",
doi = "10.1089/met.2010.1500",
language = "English (US)",
volume = "8",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Bile acid sequestrants and diabetes

T2 - Introduction and overview to the supplement

AU - Jialal, I.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.

AB - Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.

UR - http://www.scopus.com/inward/record.url?scp=78650190723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650190723&partnerID=8YFLogxK

U2 - 10.1089/met.2010.1500

DO - 10.1089/met.2010.1500

M3 - Article

C2 - 20973745

AN - SCOPUS:78650190723

VL - 8

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - SUPPL. 1

ER -